Recently, good news came from the post-doctoral workstation of Jianfeng Pharmaceutical. Under the guidance of the workstation mentor Jiang Xiaomeng, the post-doctoral researcher Yang Xiaoxiao has made new progress in the treatment of alcoholic liver disease. Related research results 《Roxadustat, a hypoxia-inducible factor 1a activator, attenuates both long- and short-term alcohol induced alcoholic liver diseaseIn the internationally renowned academic journals 《Frontiers in Pharmacologypublished in. This journal is a frontier journal in the field of international pharmacy, mainly publishing academic papers and information on basic and clinical pharmacology, medicinal chemistry, pharmacology and toxicology.

    Alcoholic liver disease is one of the main types of liver disease in the world. Its pathogenesis includes the initial alcoholic fatty liver, which further evolves into alcoholic steatohepatitis, and even liver fibrosis and cirrhosis, which may eventually deteriorate into liver cancer. Previous academic research on alcoholic liver disease mainly focused on lipid metabolism disorders, alcohol-induced inflammatory infiltration, oxidative stress in liver cells, and intestinal microbial disorders. The research results of Yang Xiaoxiao and others focused on the new role of the chronic kidney disease anemia treatment drug roxalastat in alcoholic liver disease. The therapeutic effect of roxalastat was explored by constructing acute and chronic alcoholic liver disease models, and combined with cell experiments for collaborative verification. The results show that alcohol can cause lipid metabolism disorders, but also lead to liver inflammation, oxidative stress and other adverse effects, roxalinastat by inhibiting lipid synthesis geneSREBP1c,ChREBP,FASN,ACC1,DGAT1expression, and the promotionPPARto increase fatty acid oxidation; roxazustat can also reduce the enrichment of macrophages and the release of pro-inflammatory cytokines to improve the inflammatory process; roxazustat reducesCYP2E1and promotes the expression of superoxide dismutaseSOD1It can alleviate the oxidative stress caused by alcohol. These studies suggest that roxalinastat could be a potential treatment for alcoholic liver disease.

    The research was supported by the China Postdoctoral Science Foundation and the Zhejiang Provincial Postdoctoral Program. Gao Yongyao and Yang Daigang, graduate students of Hefei University of Technology, are the co-first authors, and Yang Xiaoxiao, associate researcher, is the corresponding author.